Optimistic explanatory style and dispositional optimism in HIV-infected menTOMAKOWSKY, Janice; LUMLEY, Mark A; MARKOWITZ, Norman et al.Journal of psychosomatic research. 2001, Vol 51, Num 4, pp 577-587, issn 0022-3999Article

Simultaneous runs of the bayer VERSANT HIV-1 version 3.0 and HCV bDNA version 3.0 quantitative assays on the System 340 platform provide reliable quantitation and improved work flowELBEIK, Tarek; MARKOWITZ, Norman; NASSOS, Patricia et al.Journal of clinical microbiology (Print). 2004, Vol 42, Num 7, pp 3120-3127, issn 0095-1137, 8 p.Article

A randomized controlled trial evaluating the efficacy and safety of intermittent 3-, 4-, and 5-day cycles of intravenous recombinant human interleukin-2 combined with antiretroviral therapy (ART) versus ART alone in HIV-seropositive patients with 100-300 CD4⁺ T cellsDE BOER, Alberdina W; MARKOWITZ, Norman; LANE, H. Clifford et al.Clinical immunology (Orlando, Fla. Print). 2003, Vol 106, Num 3, pp 188-196, issn 1521-6616, 9 p.Article

Randomized, open-label study of the impact of two doses of subcutaneous recombinant interleukin-2 on viral burden in patients with HIV-1 infection and CD4⁺ cell counts of ≥300/mm³: CPCRA 059ABRAMS, Donald I; BEBCHUK, Judith D; DENNING, Teileen T et al.Journal of acquired immune deficiency syndromes (1999). 2002, Vol 29, Num 3, pp 221-231, issn 1525-4135Article